Updated hourlyHourly refreshMon, Oct 26, 2026
Travel · Food & drink
In South Sudan’s Jonglei State, recurring clashes between youth from Duk and Twic East counties have left fear and displacement in their wake.
A four-day patrol by the United Nations Mission in South Sudan (UNMISS) to Duk county witnessed firsthand the impact of the ongoing violence on local communities.
Peacekeepers had planned to visit Poktap, Padiet, Payuel and Pajut to assess security conditions in areas where revenge attacks and resource disputes have fueled tensions since 2023.
However, the patrol had to be cut short.
“Muddy and damaged roads prevented us from reaching Duk Padiet and Pajut, making Poktap our ultimate temporary base for three nights. But despite this, we actively engaged communities and authorities to identify pressing security concerns,” explained Augustine Nana Yaw Asare, Military Liaison Officer.
In Poktap, located between Padiet and Twic East, residents described an uncertain life in which even routine activities carry life-threatening risks.
“Living in Poktap right now means being trapped in the crossfire. Our survival relies on traveling between Padiet and Twic East, but movement has become nearly impossible. We are stuck, unable to buy food or essentials and are in constant fear of being attacked,” said local resident Dabora Akech Lual.
Community leaders say that conflict affects every household.
“As a father, whenever you leave home to search for food, you are overcome with fear about what might happen to your family while you are away,” revealed Chief Daniel Mawut Ajak.
For people displaced by armed violence in northern Jonglei earlier this year, Poktap offers a fragile sense of safety. Having fled one conflict, they now face insecurity, restricted movement and dwindling access to basic necessities.
Amou Ding Malang fled Panyang payam with her six children after violence reached Pajut, an attack that claimed her husband’s life.
“I long to return to Panyang, but we are trapped by both a lack of transport and the fear of being ambushed along the road,” she said.
Others face the growing threat of hunger. Thon Chuol, who was displaced from Lankien in Nyirol county, warned that dwindling food supplies and erratic rainfall were worsening an already precarious situation.
“We are now facing a different threat, hunger. Our hosts have been generous, sharing whatever little food they have, but the crisis is deepening every day.”
Yet, the presence of peacekeepers can help restore confidence and create conditions for communities to return home. About 15 kilometers towards Pajut, in Payuel payam, sustained UNMISS patrols have reassured residents of a village once deserted because of intercommunal cattle raiding and abductions.
“Following a devastating attack that left many dead and numerous herds of cattle stolen, UNMISS increased patrols. This restored our confidence to stay and encouraged some displaced families to return. We are always grateful when peacekeepers visit our village. Our earnest plea is for these security threats to be addressed once and for all,” said Mary Adhau, a local women’s leader.
But lasting peace will require more than security patrols.
Local authorities are also calling on young people, community members and the diaspora to reject revenge attacks, help rebuild trust between the two communities and refrain from using social media to incite hate.
“Such violence serves no purpose other than the destruction of our own people. We need collective action to stop it,” said Abraham Leek, Deputy Executive Director of Duk County.
Distributed by APO Group on behalf of United Nations Mission in South Sudan (UNMISS).
Oct 21 · 13:33·APO Group
Travel
Venture provides an accelerated path to Canadian travel revenues through an established partner with 1,850 agents and C$620 million in annual travel sales
Oct 21 · 12:31·Newswire.com
Education · Travel
For approximately 160 aspiring aviators from across the Atlanta metro, Oct. 20 was the day the sky stopped being the limit. Students boarded Delta’s 26th annual DREAM Flight at Hartsfield-Jackson Atlanta International Airport for the Airbus U.S. Manufacturing Facility in Mobile, Ala., for a firsthand look at the careers that could one day be theirs.
Students from local Atlanta schools and organizations including, Rex Mill Middle, Elite Scholars, the Kindezi Schools, Morrow High School, OBAP ACE Academy and The Atlanta Chapter of Tuskegee Airmen S.T.R.E.A.M. Program spent the day exploring what it takes to connect the world through flight and meeting the people who make it happen.
Rotating through four interactive experiences, students toured the Airbus A320 Final Assembly Line and took part in a scavenger hunt on aircraft manufacturing. They tackled aviation-themed activities and challenges at the Old Canteen Center, operated drones and flight simulators at Flight Works and explored the Advanced Manufacturing Program and facilities at Bishop State Community College.
Before heading home, students heard from a panel of Delta and Airbus leaders at Bishop State, including Kurt Ford, Managing Director of Flight Training; William Cossey, Managing Director of Supply Chain Management; Tyesha Gray, Director of Human Resources; Julian Anugom, Director of In-Flight Entertainment and Connectivity; and Roderick Rogers, Head of A220 Quality Product Improvement at Airbus. These leaders shared their own career journeys and answered questions about navigating the industry.
“Every student on this flight has the potential to become a pilot, engineer, technician or leader. Representation can be a powerful catalyst for unlocking potential, especially when students see people who look like them building, flying and leading in this industry. Delta’s DREAM Flight helps them better understand the variety of career pathways in the aviation industry,” said Keyra Lynn Johnson, Chief Diversity, Equity, Inclusion & Social Impact Officer.
DREAM Flight’s founder honored
This year, former Delta pilot and U.S. Air Force veteran John Bailey was inducted into the OBAP Hall of Fame at the organization’s annual conference. The honor recognizes Captain Bailey’s long career dedicated to opening doors for young people who dream of flying, from helping bring OBAP’s ACE Academy to Delta to founding Delta’s DREAM Flight.
After flying military transport aircraft for the U.S. Air Force, including missions in Vietnam, Bailey joined Delta in 1973. As a newly hired pilot based in Boston, he often flew round-robin charter flights around the city for terminally ill children, and those flights sparked the idea to create a similar experience for kids who dreamed of becoming pilots.
In July 2000, Bailey piloted the first DREAM Flight to the Smithsonian Air and Space Museum in Washington, D.C., with 150 students from Atlanta City Schools on board. An all-Black crew of Delta pilots volunteered their time to operate the flight, and members of the Tuskegee Airmen greeted students in Washington. They returned to Atlanta on time, and 26 years later, DREAM Flight remains a one-day journey from takeoff to touchdown.
Growing the next generation of aviators
Delta’s DREAM Flight bridges the gap between early curiosity and future career options by building students’ interest in aviation through fun, hands-on educational experiences and pairing them with mentors. By making these foundational experiences readily available and financially accessible, Delta’s partnership with OBAP has successfully reached more than 4,000 young people to date.
Many DREAM Flight alumni have gone on to build careers at Delta, including:
First Officer Kyle Foley was just 12 years old when he boarded the very first DREAM Flight in 2000. Seeing the pilots and controls up close for the first time set him on a path that led to a career flying for Delta.
First Officer Curtis Jackson took DREAM Flight as a teen and grew up looking up to Bailey as one of Delta’s pioneering pilots. Bailey’s advice to keep pushing himself until he reached his goals stayed with Jackson on his path to the flight deck.
DREAM Flight is one of several Delta programs, including WING Flight, ACE Academy and the National Flight Academy, that introduce students to aviation careers and expand the aviation talent pipeline.
Working together to expand horizons
Airbus and Delta have long shared common goals for the future of travel from the talent in the industry to the aircraft to get us there. Earlier this year, Delta announced the addition of 31 next-generation Airbus widebody aircraft to its fleet, an investment that will fuel international growth and accelerate fleet renewal in the years to come.
“We talk a lot about the future of aviation, but you can’t actually build that future without bringing new voices and fresh perspectives into the fold,” said Roderick Rogers, Head of A220 Quality Product Improvement in Mobile. “Opening our doors in Mobile to Delta’s DREAM flight is our way of showing these students that there is a very real, accessible place for them in this industry, whether that's in the cockpit or right here on the manufacturing floor.”
Mobile is one of five cities worldwide where Airbus commercial aircraft are assembled. The Mobile Airbus U.S. Manufacturing Facility has more than 2,000 employees who produce A320 and A220 Family aircraft for customers in the U.S. and Latin America. Earlier this fall, Delta and Airbus also partnered on Delta’s 11th annual WING (Women Inspiring Next Generation) Flight, which brought 160 young women from Atlanta to the same Mobile facility in celebration of Girls in Aviation Day.
Oct 21 · 12:30·Delta Air Lines
Gaming · Travel
Vampire spy RPG revealed during Xbox showcase event thing. Check out the trailer from IGN x ID@XBOX : YouTube | MP4 October 20, 2026 - As revealed during IGN x ID@XBOX, indie developer Wispfire and narrative game publisher Fellow Traveller have announced that Red Kiss , their Cold War vampire spy RPG, is coming to XBOX and Game Pass on Day One, alongside its previously announced PC release via Steam...
Oct 21 · 12:24·Games Press
Travel
Caravan launches a new social travel app that puts everyone traveling together on one live map, replacing endless "Where are you?" texts with real-time coordination, event-based location sharing, and shared experiences across iPhone, iPad, Apple Watch, CarPlay and Apple TV. FORT...
Oct 21 · 12:15·PRWeb
Travel
New benefit gives Hilton Honors members a more flexible way to use Points toward their stay in the Hilton Honors App Pay with Points is a new Hilton Honors benefit that allows members to use Hilton Honors Points toward eligible hotel charges during Digital Check Out in the Hilton Honors App Pay with Points is available to
Oct 21 · 12:01·Business Wire
Healthcare · Automotive
Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS)
Fenebrutinib FENhance 1 & 2 Phase III pooled data show a 55% reduction in annualised relapse rate (ARR) vs active comparator
Following European Commission paediatric approval on 15 October, new Ocrevus OPERETTA 2 Phase III data show 90% of children aged 10–17 remained relapse-free over two years
Featured in "Best of MSToronto2026", Enspryng METEOROID Phase III data highlight significant attack reduction and improved functional recovery in MOGAD, an underserved autoimmune disease
Basel, 21 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new Phase III data for investigational fenebrutinib in multiple sclerosis (MS), demonstrating reduced markers of chronic brain inflammation as well as more comprehensive disease control versus active comparators.1-3 These findings, alongside new Ocrevus® (ocrelizumab) and Enspryng® (satralizumab) data, will be featured across more than 40 abstracts at MSToronto2026 (10th ACTRIMS- ECTRIMS Meeting), held 21 to 23 October in Toronto. Highlights include a fenebrutinib late-breaking presentation and an Enspryng presentation in the “Best of MSToronto2026.4
“Addressing long-term disability progression to preserve people’s independence remains a critical challenge in neuroinflammatory diseases, and particularly in multiple sclerosis,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Our recent data indicate that fenebrutinib can inhibit disease activity inside and outside the central nervous system, underscoring its potential to transform care for people living with relapsing and primary progressive forms of multiple sclerosis.”
Fenebrutinib targets progressive biology inside the brain
New data from the pivotal trials in RMS (FENhance 1 and 2) and PPMS (FENtrepid) support the potential of fenebrutinib as the first and only high-efficacy oral medicine for both forms of MS.
Reduction of chronic active lesions (Late-breaking oral #O137): In the first prospective demonstration of a therapeutic effect on chronic active lesions in MS Phase III clinical trials, data show fenebrutinib reduced the volume of slowly expanding lesions (SELs) by up to 30% (p<0.001) in RMS (over 96 weeks) and PPMS (over 120 weeks), along with a 62% (p=0.001) reduction in accumulation of paramagnetic rim lesions (PRLs) in RMS, versus active comparators. These findings demonstrate that fenebrutinib directly targets chronic neuroinflammation in the brain, a primary driver of disability progression in MS.1
Comprehensive disease control (Poster #P1434): In the pooled RMS trials, three quarters (75%) of fenebrutinib-treated patients showed no evidence of disease activity (NEDA-3) meaning zero relapses, zero MRI activity and zero worsening disability at nearly two years, a 70% reduction (p<0.001) versus the comparator. These results show fenebrutinib’s potential to suppress disease activity and delay progression.2
Preserving brain volume and function (Oral #O089): Pooled RMS data show fenebrutinib reduced the annualised relapse rate (ARR) by 55% versus the comparator (p<0.001) over 96 weeks. In addition, fenebrutinib reduced annual total brain volume loss by 23% (p<0.001) and 12-week composite confirmed disability progression by 16% (p=0.04). These findings demonstrate fenebrutinib’s potential to control relapses, to slow brain tissue loss caused by neuronal cell death and to preserve function.3
Ocrevus provides consistent benefits across all age groups
New data show that Ocrevus provides significant and consistent efficacy across a broad MS patient population, from children 10 years of age to older adults.
Two-year data and immune function in paediatric MS (3 posters on the Phase III OPERETTA 2 study): 90% of children with relapsing-remitting MS (RRMS) treated with Ocrevus, who were 10-17 years old at trial entry, remained free of relapses over two years (#P1439).5 Ocrevus selectively depleted target B cells with little to no effect on other immune cells (#P1407), while preserving pre-existing immunity to common childhood vaccines in 81–100% of patients (#P1415). The European Commission approved Ocrevus in this indication on 15 October, following FDA approval in May.6,7
Two-year data in patients >55 years old (Poster #P1426 on the Phase IIIb CONSONANCE study): 53% of participants over 55 years old treated with Ocrevus showed no disability progression after two years, similarly to younger participants (55%), showing Ocrevus maintains its effect on progression as people age.8
Switching from other treatments to Ocrevus: Real-world data show progression was the leading reason for patients switching from ofatumumab to Ocrevus (ePoster #EP2733).9 A separate analysis of patients treated with Ocrevus or ofatumumab for one year show Ocrevus was associated with lower MRI lesion activity (Poster #P0305).10
Enspryng reduces risk of attack and is associated with improved recovery
Exploratory analyses of the pivotal METEOROID trial suggest that in addition to significantly lowering the risk of relapse (AAN 2026), Enspryng was associated with improved recovery and reduced disability progression, which is critical to prevent permanent damage to the optic nerves, spinal cord or brain in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). These findings reinforce Enspryng’s potential to become the first FDA-approved treatment for MOGAD, with a decision in the U.S. expected in January 2027.4,11
Relapse recovery (Oral #O035): Patients treated with Enspryng achieved numerically superior recovery at 12 weeks post relapse versus placebo (median change in Expanded Disability Status Scale [EDSS] of -2 vs -0.5). Overall function was stable (median 0) with Enspryng, compared to worsening (median 0.5) with placebo, as measured with the EDSS at the end of the double-blind period or first relapse.4
About fenebrutinib
Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimised pharmacokinetics (PK) profile. Fenebrutinib can act throughout the body and also cross the blood-brain barrier into the CNS to target chronic inflammation. It is uniquely designed to target relapsing and progressive biology by inhibiting cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression.
While most current BTK inhibitors are covalent and irreversible, meaning they form a permanent chemical bond with the enzyme, fenebrutinib is non-covalent and reversible, meaning it binds and then eventually releases the enzyme.
About Ocrevus® (ocrelizumab)
Ocrevus is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. Ocrevus IV and Ocrevus subcutaneous (SC; marketed as Ocrevus Zunovo® [ocrelizumab hyaluronidase-ocsq] in the U.S.) are the only therapies approved for both RMS (including relapsing-remitting multiple sclerosis [RRMS] and active, secondary progressive multiple sclerosis [SPMS], as well as clinically isolated syndrome [CIS] in the U.S.) and primary progressive multiple sclerosis (PPMS). Both Ocrevus IV and SC are administered every six months. The initial IV dose is given as two 300 mg infusions two weeks apart with subsequent doses given as single 600 mg infusions. Ocrevus SC is given as a single 920 mg subcutaneous injection every six months.
About Enspryng® (satralizumab)
Enspryng, developed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that binds to both soluble and membrane-bound interleukin-6 receptors (IL-6R), thereby inhibiting IL-6 mediated signalling, a key pathway involved in inflammation. Enspryng incorporates Chugai’s proprietary antibody recycling technology, which enables pH-dependent binding to IL-6R and repeated engagement of the target, extending antibody circulation and supporting sustained inhibition of IL-6 mediated signalling.
Enspryng is the first and only IL-6R inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the U.S. and E.U., with a well-established safety profile in over 16,000 patients. Enspryng was also recently approved for the treatment of thyroid eye disease (TED) in the U.S.
Roche is committed to developing Enspryng in additional neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 mediated signalling, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE).
About Roche in Neurology
Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally.
Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and cerebrospinal fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today.
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
[1] Oh J, et al. Fenebrutinib Shows a Therapeutic Effect on MS Progressive Biology: Outcomes on Paramagnetic Rim Lesions and Slowly Expanding Lesions in the Phase III FENhance I/II and FENtrepid Trials in Relapsing and Primary Progressive Multiple Sclerosis (#O137). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 23 October 2026; Toronto, Canada.
[2] Cerqueira JJFCA, et al. No Evidence of Disease Activity With Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase III FENhance 1 and 2 Trials (#P1434). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[3] Sormani MP, et al. Efficacy of Fenebrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis: Pooled Analysis Results From the FENhance 1 and 2 Studies (#O089). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 21 October 2026; Toronto, Canada.
[4] Marignier R, et al. Severity and Recovery of Relapses in Patients with Relapsing MOGAD Treated with Satralizumab: Results from the Phase 3 METEOROID Study (#O035). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[5] Deiva K, et al. OPERETTA 2: Continued Follow-Up of the Efficacy and Safety Profile of Ocrelizumab in Pediatric Relapsing-Remitting MS (#P1439). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[6] Bar-Or A, et al. Impact of Ocrelizumab vs Fingolimod on Immune Function in Pediatric Patients With MS in the OPERETTA 2 Study (#P1407). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[7] Banwell B, et al. Vaccination and Disease-Modifying Therapies: Impact of Ocrelizumab vs Fingolimod on Preexisting Vaccine Seropositivity and Vaccine-Preventable Infections in Pediatric Patients With MS in OPERETTA 2 (#P1415). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[8] Butzkueven H, et al. Ocrelizumab Maintains Clinical and Safety Outcomes in Older Patients (>55 Years) with Progressive Multiple Sclerosis: 2-Year Results from the CONSONANCE Study (#P1426). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[9] Marriott J, et al. Switching Patients with Multiple Sclerosis from Ofatumumab to Ocrelizumab: A Real-World Study of Canadian Healthcare Professionals (#EP2733). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 21-23 October 2026; Toronto, Canada.
[10] Ziemssen T, et al. Brain Volume Loss and T2 Lesion Activity in RRMS: Real-World Longitudinal Comparison of Ocrelizumab vs. Ofatumumab (#P0305). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 21 October 2026; Toronto, Canada.
[11] Levy M, et al. Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial (PL5.006). Presented at: 78th Annual Meeting of the American Academy of Neurology (AAN) 2026; 21 April 2026; Chicago, IL, USA.
Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com
Tristan Schmitz
Phone: +41 79 529 70 35Lorena Corfas
Phone: +41 79 568 24 95
Simon Goldsborough
Phone: +44 797 32 72 915Karsten Kleine
Phone: +41 79 461 86 83
Kirti Pandey
Phone: +41 79 398 38 53Yvette Petillon
Phone: +41 79 961 92 50
Irène Stephan
Phone: +41 79 377 83 75Albert Thottiyil
Phone: +41 79 775 66 12
Roche Investor Relations
Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.comDr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Attachment
Media&Investor Release MSToronto2026 English
Oct 21 · 12:00·Roche
Travel
Steam demo now live. Most post-apocalyptic games ask you to pull the trigger, Wasteland Gunsmith Simulator asks you to build the gun. Demo officially launched on PC and is taking part in the Steam Next Fest! This cozy management sim puts players in the boots of the wasteland’s most indispensable survivor: a traveling gunsmith...
Oct 21 · 12:00·Games Press
AI · Travel
MADRID, October 21, 2026--Amadeus and NVIDIA have been collaborating to explore how accelerated computing and travel-specific AI could support faster, more scalable and more efficient flight search. Building on this work, the companies have now signed a Memorandum of Understanding (MoU) to deepen their
Oct 21 · 12:00·Business Wire
Travel
TEG SPV LLC (“TEG”), an integrated hospitality, tourism and events business based in Uzbekistan, has entered the U.S. public markets, becoming the first company from Uzbekistan to be publicly traded in the United States. The historic milestone opens a new chapter for TEG as it se…
Oct 21 · 11:19·PR Now
Finance · Healthcare
NEW YORK, October 21, 2026--OneSpaWorld Holdings Limited, (NASDAQ: OSW), the pre-eminent global provider of health and wellness products and services on board cruise ships and in destination resorts around the world, announced today that it will release its Third Quarter Fiscal 2026 earnings on Wednesd
Oct 21 · 10:45·Business Wire
Energy · Travel
Lesotho and Germany are exploring opportunities to strengthen economic cooperation and attract investment following a business roundtable held in Berlin ahead of the Berlin Global Dialogue 2026.
The Deputy Prime Minister, Justice Nthomeng Majara, called for stronger business partnerships to create jobs and support economic growth. She highlighted investment opportunities in renewable energy, water management, agriculture, textiles, manufacturing and tourism. Minister of Foreign Affairs and International Relations, Honourable Limpho Tau, encouraged German investors to explore these sectors, citing Lesotho’s water resources, wind and solar energy potential, and skilled workforce.
Mr. Claus Mayer of the Federal Association for Economic Development and Foreign Trade highlighted Germany’s technological expertise as an opportunity to support Lesotho’s industrial development, sustainable infrastructure and vocational training. He reaffirmed the BWA’s commitment to connecting businesses and promoting investment that benefits both countries.
Distributed by APO Group on behalf of Government of Lesotho.
Oct 21 · 10:21·APO Group